Skip to main content
. Author manuscript; available in PMC: 2016 Dec 7.
Published in final edited form as: J Thorac Cardiovasc Surg. 2015 Sep 28;151(2):589–97.e2. doi: 10.1016/j.jtcvs.2015.09.090

APPENDIX E2.

Deyo–Charlson comorbidities by standard versus extended use of antibiotic prophylaxis

Comorbidities Antibiotic prophylaxis
P value*
Standard
Extended
N % N %
Deyo–Charlson comorbidity grouping
 Myocardial infarction 46,017 37.6 12,416 38.3 .02
 Congestive heart failure 23,970 19.6 6622 20.4 <.01
 Peripheral vascular disease 18,933 15.5 4648 14.3 <.01
 Cerebrovascular disease 11,696 9.6 3033 9.4 .27
 Dementia 359 0.3 89 0.3 .57
 Chronic pulmonary disease 30,157 24.6 7226 22.3 <.01
 Rheumatologic disease 2331 1.9 619 1.9 .96
 Peptic ulcer disease 1800 1.5 451 1.4 .28
 Mild liver disease 1844 1.5 492 1.5 .89
 Moderate/severe liver disease 202 0.2 55 0.2 .86
 Diabetes 44,951 36.7 12,272 37.9 <.01
 Diabetes with chronic complications 6857 5.6 1591 4.9 <.01
 Hemiplegia or paraplegia 589 0.5 185 0.6 .04
 Renal disease 15,156 12.4 3677 11.3 <.01
 Any malignancy 2983 2.4 758 2.3 .30
 Metastatic solid tumor 316 0.3 63 0.2 .04
*

Chi-square test.